FGFR2 and melanoma: An AZD4547, which belongs to the first generation of selective FGFR inhibitors [11] and is currently in phase II of clinical trials in patients with solid tumours, including melanoma and lymphomas, that have progressed following at least one line of standard treatment (NCT02465060), as well as in urothelial carcinoma patients with FGFR2/3 gene alterations (NCT05086666), was also tested.